Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or nonpregnant, nonlactating female subjects~* Meets criteria for definite rheumatoid arthritis as defined by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification at screening~* Has active disease defined as a score of \>3.2 on DAS28-ESR prior to study drug administration despite dual-DMARD treatment~* Is on a stable dose of ≤ 20 mg per week of methotrexate for at least 8 weeks AND a stable dose of an allowed DMARD for at least 24 weeks prior to the screening visit~* May also be on a stable dose of 10 mg or less of prednisone or other the dose equivalent of another corticosteroid for 4 weeks prior to study drug administration~Exclusion Criteria:~* Has current rheumatoid disease or inflammatory joint disease other than RA~* Has any history of use of adrenocorticotropic hormone (ACTH) for the treatment of RA~* Has taken B-cell mediated therapies in the 6 months prior to screening~* Has hepatitis B, hepatitis C, history of tuberculosis (TB) or other contraindication as per the United States (US) Prescribing Information for Acthar~* Has history of Type 1 or Type 2 diabetes~* Has any clinically significant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: All Enrolled Participants (Type: EXPERIMENTAL): All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
- Part 2: Acthar Gel (Type: EXPERIMENTAL): Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
- Part 2: Placebo (Type: PLACEBO_COMPARATOR): Participants receive Placebo 1 mL twice weekly for an additional 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).